[go: up one dir, main page]

SV2018005610A - Derivados de oxopiridina sustituidos - Google Patents

Derivados de oxopiridina sustituidos

Info

Publication number
SV2018005610A
SV2018005610A SV2018005610A SV2018005610A SV2018005610A SV 2018005610 A SV2018005610 A SV 2018005610A SV 2018005610 A SV2018005610 A SV 2018005610A SV 2018005610 A SV2018005610 A SV 2018005610A SV 2018005610 A SV2018005610 A SV 2018005610A
Authority
SV
El Salvador
Prior art keywords
oxopiridine
derivatives
substituted
thermal
bottombodious
Prior art date
Application number
SV2018005610A
Other languages
English (en)
Inventor
Nunes Eloisa Jimenez
Jens Ackerstaff
Susanne Röhrig
Alexander Hillisch
Katharina Meier
Jan Stampfuss
Pascal Ellerbrock
Daniel Meibom
Dieter Lang
Stefan Heitmeier
Adrian Tersteegen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SV2018005610A publication Critical patent/SV2018005610A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE A DERIVADOS DE OXOPIRIDINA SUSTITUIDOS Y A PROCESOS PARA SU PREPARACIÓN, Y TAMBIÉN A SU USO PARA PREPARAR MEDICAMENTOS PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES, EN PARTICULAR ENFERMEDADES CARDIOVASCULARES, PREFERENTEMENTE TRASTORNOS TROMBÓTICOS O TROMBOEMBÓLICOS, Y EDEMAS, Y TAMBIÉN TRASTORNOS OFTÁLMICOS
SV2018005610A 2015-07-09 2018-01-08 Derivados de oxopiridina sustituidos SV2018005610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15176099 2015-07-09
EP16157350 2016-02-25

Publications (1)

Publication Number Publication Date
SV2018005610A true SV2018005610A (es) 2018-04-27

Family

ID=56345141

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005610A SV2018005610A (es) 2015-07-09 2018-01-08 Derivados de oxopiridina sustituidos

Country Status (39)

Country Link
US (4) US10421742B2 (es)
EP (1) EP3319956B1 (es)
JP (1) JP6871180B2 (es)
KR (1) KR102596164B1 (es)
CN (2) CN108026072B (es)
AU (1) AU2016289746B2 (es)
CA (1) CA2990901C (es)
CL (1) CL2018000039A1 (es)
CO (1) CO2018000113A2 (es)
CR (1) CR20180017A (es)
CU (1) CU24512B1 (es)
CY (1) CY1123996T1 (es)
DK (1) DK3319956T3 (es)
DO (1) DOP2018000004A (es)
EA (1) EA036208B1 (es)
EC (1) ECSP18001308A (es)
ES (1) ES2856554T3 (es)
GE (2) GEP20197046B (es)
HR (1) HRP20210459T1 (es)
HU (1) HUE053552T2 (es)
IL (1) IL256556B (es)
JO (1) JO3703B1 (es)
LT (1) LT3319956T (es)
MA (1) MA42376B1 (es)
MX (1) MX377903B (es)
MY (1) MY196640A (es)
NI (1) NI201800001A (es)
PE (1) PE20180538A1 (es)
PH (1) PH12018500057A1 (es)
PL (1) PL3319956T3 (es)
RS (1) RS61584B1 (es)
SI (1) SI3319956T1 (es)
SV (1) SV2018005610A (es)
TN (1) TN2018000011A1 (es)
TW (1) TWI717367B (es)
UA (1) UA122341C2 (es)
UY (1) UY36780A (es)
WO (1) WO2017005725A1 (es)
ZA (1) ZA201800826B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197896B1 (de) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN107428689A (zh) * 2015-03-19 2017-12-01 拜耳制药股份公司 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
RU2742771C2 (ru) 2016-08-31 2021-02-10 Цзянсу Хэнжуй Медицин Ко., Лтд. Производное оксопиколинамида, способ его получения и его фармацевтическое применение
MY201167A (en) * 2018-03-15 2024-02-08 Bayer Ag Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives
IL277811B2 (en) 2018-04-10 2023-12-01 Bayer Pharma AG A consequence of oxopyridine is transformed
WO2020007256A1 (zh) 2018-07-02 2020-01-09 江苏恒瑞医药股份有限公司 一种氧代吡啶酰胺类衍生物的晶型及制备方法
AR115870A1 (es) 2018-07-31 2021-03-10 Sumitomo Chemical Co MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ
US20220306602A1 (en) * 2018-12-17 2022-09-29 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
EP3898634A1 (en) 2018-12-21 2021-10-27 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
JP2022514303A (ja) 2018-12-21 2022-02-10 バイエル・アクチエンゲゼルシヤフト 置換されているオキソピリジン誘導体
CN114206854B (zh) * 2019-09-27 2023-02-24 深圳信立泰药业股份有限公司 FXIa抑制剂及其制备方法和医药用途
JP7700218B2 (ja) 2020-09-17 2025-06-30 浙江海正薬業股▲ふん▼有限公司 ピペラジン誘導体、その製造方法、およびその使用
CN114621140B (zh) * 2020-12-10 2023-08-11 中国科学院上海药物研究所 芳基二氟乙酰胺化合物及其制备方法和用途
IL305235A (en) 2021-03-09 2023-10-01 Bayer Ag Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
KR20230155505A (ko) * 2021-03-09 2023-11-10 바이엘 악티엔게젤샤프트 (4s)-24-클로로-4-에틸-73-플루오로-35-메톡시-32,5-디옥소-14-(트리플루오로-메틸)-32h-6-아자-3(4,1)-피리디나-1(1)-[1,2,3]트리아졸라-2(1,2),7(1)-5 디벤제나헵타판-74-카르복스아미드의 결정질 형태
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
CN113666826B (zh) * 2021-07-30 2024-03-26 五邑大学 一种芳基或杂芳基甲氧基化反应的方法
CN116199672A (zh) * 2021-11-30 2023-06-02 成都泰和伟业生物科技有限公司 一种嘧啶酰胺类衍生物及其制备方法和用途
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116262735B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262734B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 氧代吡啶类化合物及其制备方法和用途
CN116082303B (zh) * 2022-12-21 2025-02-25 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其中间体和应用
CN116262736B (zh) * 2022-12-26 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
KR20250164210A (ko) 2023-03-31 2025-11-24 바이엘 악티엔게젤샤프트 (4s)-24-클로로-4-에틸-73-플루오로-35-메톡시-32,5-디옥소-14-(트리플루오로메틸)-32h-6-아자-3(4,1)-피리디나-1(1)-[1,2,3]트리아졸라-2(1,2),7(1)-디벤제나헵타판-74-카르복스아미드를포함하는 제약 투여 형태
WO2024251276A1 (zh) 2023-06-09 2024-12-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体和应用
CN116751136B (zh) * 2023-06-21 2025-08-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621728B (zh) * 2023-06-09 2025-07-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621742B (zh) * 2023-06-09 2025-05-06 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用
CN116874387B (zh) * 2023-06-21 2025-08-26 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116730861A (zh) * 2023-06-21 2023-09-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
TW202515882A (zh) 2023-06-30 2025-04-16 大陸商深圳信立泰藥業股份有限公司 一種多取代的大環化合物及其製備方法與應用
CN117164561A (zh) * 2023-09-07 2023-12-05 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164563B (zh) * 2023-09-07 2025-06-10 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN117164565B (zh) * 2023-09-07 2025-05-27 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164566B (zh) * 2023-09-07 2025-06-06 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164562B (zh) * 2023-09-07 2025-06-13 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164564B (zh) * 2023-09-07 2025-07-08 成都施贝康生物医药科技有限公司 氧代哒嗪类化合物及其制备方法和用途
CN117186073B (zh) * 2023-09-08 2025-06-06 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN118894814B (zh) * 2024-07-15 2025-09-12 上海康鹏科技股份有限公司 1-(2-溴-4-氯苯基)-4-(三氟甲基)-1h-1，2，3-三唑的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6642252B2 (en) 2000-11-07 2003-11-04 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
EP1526131A1 (en) 2003-10-22 2005-04-27 Graffinity Pharmaceuticals Aktiengesellschaft Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7763608B2 (en) 2006-05-05 2010-07-27 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
GB2497806A (en) 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
ES2655669T3 (es) 2011-12-21 2018-02-21 Ono Pharmaceutical Co., Ltd. Derivados de piridinona y pirimidinona como inhibidores del factor XIa
SI2880026T1 (sl) * 2012-08-03 2017-04-26 Bristol-Myers Squibb Company Dihidropiridon p1 kot faktor xia inhibitorjev
HK1220406A1 (zh) 2013-03-14 2017-05-05 Chdi Foundation, Inc. 组蛋白去乙酰酶抑制剂及组合物
EP2978425B1 (en) * 2013-03-27 2017-09-27 Merck Sharp & Dohme Corp. Factor xia inhibitors
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
WO2015011087A1 (de) 2013-07-23 2015-01-29 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate und ihre verwendung als faktor xia / plasma
CN105849109B (zh) * 2013-10-30 2018-01-23 拜耳制药股份公司 取代的氧代吡啶衍生物
CN106132962B (zh) 2014-01-31 2018-09-07 百时美施贵宝公司 作为凝血因子xia抑制剂的具有芳族p2’基团的大环化合物
EP3138839B1 (en) 2014-02-14 2020-10-28 Sichuan Haisco Pharmaceutical Co., Ltd. Pyridone or pyrimidone derivative, preparation method therefor and application thereof
US10138236B2 (en) 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
US10414731B2 (en) 2014-09-24 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2016046156A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
US20170298052A1 (en) 2014-09-24 2017-10-19 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
EP3197896B1 (de) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2016046166A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
CN108137549B (zh) * 2015-08-05 2021-07-20 百时美施贵宝公司 取代的甘氨酸衍生的fxia抑制剂

Also Published As

Publication number Publication date
GEAP201914692A (en) 2019-08-12
JP2018519323A (ja) 2018-07-19
CR20180017A (es) 2018-03-07
RS61584B1 (sr) 2021-04-29
NZ739109A (en) 2024-09-27
UA122341C2 (uk) 2020-10-26
DK3319956T3 (da) 2021-03-29
GEP20197046B (en) 2019-12-10
EA036208B1 (ru) 2020-10-14
EA201890111A1 (ru) 2018-06-29
MX377903B (es) 2025-03-10
BR112018000209A2 (pt) 2018-09-04
NI201800001A (es) 2018-10-19
JO3703B1 (ar) 2021-01-31
US20250282748A1 (en) 2025-09-11
CA2990901C (en) 2024-11-12
WO2017005725A1 (en) 2017-01-12
PL3319956T3 (pl) 2021-07-05
US11180471B2 (en) 2021-11-23
LT3319956T (lt) 2021-02-10
CU20180001A7 (es) 2018-06-05
CN108026072B (zh) 2021-08-17
DOP2018000004A (es) 2018-01-31
PH12018500057A1 (en) 2018-07-09
TWI717367B (zh) 2021-02-01
ZA201800826B (en) 2021-08-25
CO2018000113A2 (es) 2018-06-12
CN108026072A (zh) 2018-05-11
AU2016289746B2 (en) 2020-08-20
US20180194745A1 (en) 2018-07-12
MA42376A (fr) 2018-05-16
CN113292539B (zh) 2023-12-22
KR102596164B1 (ko) 2023-11-01
US10421742B2 (en) 2019-09-24
TN2018000011A1 (en) 2019-07-08
JP6871180B2 (ja) 2021-05-12
CU24512B1 (es) 2021-05-12
MA42376B1 (fr) 2021-04-30
CA2990901A1 (en) 2017-01-12
HRP20210459T1 (hr) 2021-05-14
HUE053552T2 (hu) 2021-07-28
ECSP18001308A (es) 2018-03-31
CY1123996T1 (el) 2022-07-22
US20230024752A1 (en) 2023-01-26
PE20180538A1 (es) 2018-03-20
CN113292539A (zh) 2021-08-24
ES2856554T3 (es) 2021-09-27
CL2018000039A1 (es) 2018-07-13
TW201706261A (zh) 2017-02-16
IL256556B (en) 2021-02-28
MX2018000076A (es) 2018-02-26
EP3319956A1 (en) 2018-05-16
IL256556A (en) 2018-02-28
EP3319956B1 (en) 2021-01-06
KR20180026761A (ko) 2018-03-13
US20190367478A1 (en) 2019-12-05
AU2016289746A1 (en) 2018-01-25
UY36780A (es) 2017-01-31
MY196640A (en) 2023-04-25
HK1255045A1 (zh) 2019-08-02
SI3319956T1 (sl) 2021-02-26

Similar Documents

Publication Publication Date Title
SV2018005610A (es) Derivados de oxopiridina sustituidos
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PT3681872T (pt) Beta-hidroxietilaminas substituídas com heteroarilo para utilização no tratamento de hiperglicemia
CL2016001895A1 (es) Compuestos
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2018002811A1 (es) Derivados de aminotiazol útiles como agentes antivíricos.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY35745A (es) Derivados sustituidos de fenilalanina
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
NI201900023A (es) 1 - arilnaftiridin-3-carboxamidas 7-sustituidas y su uso
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
MX364704B (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.